Study to Evaluate Imatinib in Desmoid Tumors

NCT01137916 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Aggressive Fibromatosis
Desmoid Tumor

Interventions

DRUG: Imatinib

Sponsor

Heidelberg University

Collaborators

[object Object]